CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation-Reference-Cited by-同舟云学术

CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation

Published:2021-08-17 Issue:9 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Takahashi Takuto¹²³^ORCID,Mohamud Maryam A.³,Smith Angela R.²⁴,Jacobson Pamala A.³,Jaber Mutaz M.³,Alharbi Abeer F.³,Fisher James³,Kirstein Mark N.³⁴^ORCID

Affiliation:

1. Division of Hematology and Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA

2. Division of Blood and Marrow Transplant, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, USA

3. Department of Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, Minnesota, USA

4. Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA

Abstract

Prophylactic voriconazole use is recommended for children undergoing hematopoietic cell transplantation (HCT). Dosing considerations are essential, due to the narrow therapeutic window of voriconazole.

Funder

Hematology Oncology Pharmacist Association Foundation

Division of Blood and Marrow Transplant, Department of Pediatrics, University of Minnesota

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00623-21

Reference51 articles.

1. Fungal infections in primary immunodeficiencies

2. Pediatric Invasive Aspergillosis: A Multicenter Retrospective Analysis of 139 Contemporary Cases